MediciNova, Inc. 2012 Form 10-K Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on small-molecule therapeutics for serious diseases with unmet medical needs. The filing covers the fiscal year ended December 31, 2012, including fourth-quarter results. The company had no approved products, no product sales, and 12 full-time employees.
Primary programs were MN-166 (ibudilast) for neurological disorders, including methamphetamine addiction, opioid withdrawal, progressive multiple sclerosis and pain, and MN-221 (bedoradrine) for acute asthma and COPD exacerbations. The company also maintained earlier-stage or inactive programs covering additional indications.
Financial results and key metrics
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Revenue | $0.803 million | $0 | New revenue in 2012 |
| Research and development expense | $5.013 million | $7.785 million | Down $2.772 million |
| General and administrative expense | $6.735 million | $8.324 million | Down $1.589 million |
| Total operating expenses | $11.748 million | $16.108 million | Down $4.360 million |
| Operating loss | $10.945 million | $16.108 million | Improved by $5.163 million |
| Net loss | $10.961 million | $17.734 million | Improved by $6.773 million |
| Basic and diluted loss per share | $0.66 loss | $1.20 loss | Improved |
| Cash used in operating activities | $11.864 million | $13.309 million | Improved by $1.444 million |
| Cash and cash equivalents | $4.011 million | $15.093 million | Down $11.083 million |
| Working capital | $3.384 million | $12.010 million | Down $8.626 million |
Revenue consisted of recognition of a portion of the $2.5 million non-refundable upfront payment received from Kissei for MN-221 research and development services. The company recorded no cost of revenue in 2012; expenses related to the services were included in research and development.
At December 31, 2012, total assets were $19.568 million, total liabilities were $4.688 million and stockholders’ equity was approximately $14.880 million. The balance sheet included $9.600 million of goodwill, $4.800 million of in-process research and development and a $0.667 million investment in the Zhejiang Sunmy joint venture.
MediciNova had no debt and no interest expense in 2012, compared with $1.595 million of interest expense in 2011. The company has never paid dividends and does not expect to pay dividends in the foreseeable future.
Fourth-quarter 2012 results
| Metric | Q4 2012 |
|---|---|
| Revenue | $34,000 |
| Total operating expenses | $2.455 million |
| Net loss | $2.434 million |
| Basic and diluted loss per share | $0.14 loss |
Q4 operating expenses declined from $3.503 million in Q4 2011, while the filing does not provide comparable Q4 2011 revenue.
Material changes versus the prior comparable period
- Revenue began in 2012 as Kissei-sponsored research and development services were performed.
- Research and development spending declined primarily because the MN-221 asthma Phase 2 trial was completed in March 2012; spending on the MN-221 COPD trial partially offset the reduction.
- General and administrative expense decreased due to lower employee compensation, including stock-based compensation, and lower legal and accounting fees.
- The 2011 debt was fully repaid; the company had no debt at December 31, 2012.
- Cash declined substantially as operating cash burn exceeded financing proceeds. The company invested $680,000 for a 30% interest in Zhejiang Sunmy in March 2012.
- As of December 31, 2012, MediciNova had issued or sold 856,060 shares to Aspire Capital for $1.5 million of gross proceeds. Subsequent to year-end, it sold an additional 800,000 shares for $1.5 million; total proceeds under the agreement reached $3.0 million by the filing date.
Development, outlook, risks and unusual items
- The MN-221 asthma Phase 2 trial did not statistically meet its primary FEV1 endpoint, although the company reported improvement in certain FEV1 measures, reduced hospital admissions and no clinically significant safety or tolerability issues.
- Following an October 2012 FDA meeting, the FDA identified MN-221’s risk-benefit profile as a key development issue and indicated that a pivotal trial would need a clinical outcome such as reduced hospitalizations. Further MN-221 development is dependent on funding and potentially a partner, and manufacturing requirements remained to be addressed.
- MN-166 received FDA Fast Track designation for methamphetamine dependence. NIDA-funded trials for methamphetamine addiction and opioid withdrawal were ongoing or planned, with additional investigator-sponsored work in medication-overuse headache.
- Management expected research and development expense to decline in 2013 relative to 2012 unless additional capital or strategic alliances funded new clinical development.
- The company expected approximately $3 million of cash as of March 31, 2013 and approximately $6 million of spending from April 1 through December 31, 2013, assuming additional capital was raised.
- Management stated that available working capital was sufficient to fund operations only through June 30, 2013. Recurring losses, limited cash and the need for additional financing raised substantial doubt about the company’s ability to continue as a going concern. The independent auditor included a going-concern explanatory paragraph.
- If financing is unavailable, management may need to delay or eliminate programs, sell program rights or cease operations. Additional equity financing could materially dilute existing shareholders.
- Potential future milestone payments under license agreements totaled approximately $94.1 million, although timing was uncertain and no minimum royalties were required.
- The company had a pending former-employee dispute in arbitration but did not expect it to have a material adverse effect based on its assessment at the filing date.
- Ernst & Young issued an unqualified opinion on the financial statements and an unqualified opinion on internal control over financial reporting.
Most important facts for investors to verify
- Whether MediciNova secured sufficient financing after the filing date to address the stated June 30, 2013 liquidity horizon.
- The terms, pace and dilution impact of additional Aspire Capital share sales and other equity financings.
- Progress, funding and partnership status of MN-166 clinical programs, particularly methamphetamine dependence and progressive multiple sclerosis.
- Whether MN-221 can satisfy FDA requirements for a pivotal hospitalization-outcome trial and whether a development partner is obtained.
- The remaining deferred revenue and timing of completion of Kissei-sponsored services.
- Potential license milestone obligations, manufacturing requirements and the status of the Zhejiang Sunmy sublicense for China.
- Whether goodwill, in-process research and development and the Zhejiang Sunmy investment remain recoverable if programs are delayed or discontinued.